Literature DB >> 36105335

Application of Compositions Comprising a KRAS G12C Inhibitor and an EGFR Inhibitor for the Potential Treatment of Cancer.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2022        PMID： 36105335      PMCID： PMC9465978          DOI： 10.1021/acsmedchemlett.2c00353

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Drugging the Next Undruggable KRAS Allele-Gly12Asp.

Authors:  Qinheng Zheng; D Matthew Peacock; Kevan M Shokat
Journal:  J Med Chem       Date:  2022-02-15       Impact factor: 7.446

2.  Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.

Authors:  Christian Johnson; Deborah L Burkhart; Kevin M Haigis
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

Review 3.  Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.

Authors:  Hannah Zaryouh; Ines De Pauw; Hasan Baysal; Marc Peeters; Jan Baptist Vermorken; Filip Lardon; An Wouters
Journal:  Med Res Rev       Date:  2021-04-29       Impact factor: 12.944

Review 4.  Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.

Authors:  Manzar Alam; Shoaib Alam; Anas Shamsi; Mohd Adnan; Abdelbaset Mohamed Elasbali; Waleed Abu Al-Soud; Mousa Alreshidi; Yousef MohammedRabaa Hawsawi; Anitha Tippana; Visweswara Rao Pasupuleti; Md Imtaiyaz Hassan
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

Review 5.  Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.

Authors:  Damien Reita; Lucile Pabst; Erwan Pencreach; Eric Guérin; Laurent Dano; Valérie Rimelen; Anne-Claire Voegeli; Laurent Vallat; Céline Mascaux; Michèle Beau-Faller
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

Review 6.  Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.

Authors:  Krishna Babu Duggirala; Yujin Lee; Kwangho Lee
Journal:  Biomol Ther (Seoul)       Date:  2022-01-01       Impact factor: 4.634
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.